We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Biocryst Pharmaceuticals Inc (BCRX) Com Stk USD 0.01

Sell:$5.30 Buy:$5.98 Change: $0.11 (1.89%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.11 (1.89%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.11 (1.89%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers and commercializes oral, small-molecule medicines. The Company focuses on oral treatments for rare diseases, in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), BCX9930, BCX9250, PERAMIFLU (peramivir injection), galidesivir, and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. BCX9930 is an oral, potent, and selective small molecule inhibitor of Factor D. Galidesivir is a broad-spectrum antiviral that is active against viral families.

Contact details

4505 Emperor Blvd Ste 200
United States
+1 (919) 8591302

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.16 billion
Shares in issue:
204.81 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Jon Stonehouse
    President, Chief Executive Officer, Director
  • Anthony Doyle
    Chief Financial Officer
  • Charles Gayer
    Chief Commercial Officer
  • Helen Thackray
    Chief Research & Development Officer
  • Alane Barnes
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.